Abraham Vandiver
Family · Escondido, CANPI 1982176947
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $49,629 of the $68,991 with a category attached, or 71.9%. Corcept Therapeutics accounts for 91.9% of it on its own, with 24 other manufacturers making up the rest. 2025 is the largest year on record at $35,236, more than ten times the $2,230 reported in 2021. Among family clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 398 payments — averaging $173.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Corcept Therapeutics$63K
- Novo Nordisk$2K
- Amgen$932
- AbbVie$488
- AstraZeneca$451
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$287
- plus $2K from 19 others
What the payments were for
- Consulting fees$5501%
- Speaking & faculty fees$49,62972%
- Travel & lodging$10,02815%
- Food & beverage$8,78413%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Corcept Therapeutics | 160 | $63,437 |
| Novo Nordisk | 76 | $1,720 |
| Amgen | 43 | $932 |
| AbbVie | 18 | $488 |
| AstraZeneca | 17 | $451 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 7 | $287 |
| Bayer | 7 | $286 |
| Merck | 5 | $205 |
| Lilly USA, LLC | 6 | $184 |
| Tandem Diabetes Care, Inc. | 4 | $170 |
| Johnson & Johnson | 13 | $143 |
| GSK | 4 | $126 |
| Esperion Therapeutics, Inc. | 15 | $121 |
| Boehringer Ingelheim | 4 | $75 |
| Amarin Pharma, Inc. | 4 | $65 |
| Novartis | 4 | $61 |
| Dexcom, Inc. | 1 | $55 |
| Biohaven Pharmaceuticals, Inc. | 2 | $39 |
| Xeris Pharmaceuticals, Inc. | 2 | $37 |
| Pfizer | 1 | $20 |
| Redhill Biopharma Inc. | 1 | $19 |
| Smith+Nephew | 1 | $19 |
| Hologic Sales And Service, LLC | 1 | $19 |
| Boston Scientific | 1 | $17 |
| Sanofi-aventis U.S. LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$68,991 in reported general payments places this provider in the 95th percentile of 10,634 family providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| KorlymMifepristone | 78 | $2,036,246 |
| OzempicSemaglutide | 507 | $487,240 |
| FarxigaDapagliflozin Propanediol | 487 | $313,165 |
| RybelsusSemaglutide | 291 | $294,754 |
| DapagliflozinDapagliflozin Propanediol | 334 | $176,722 |
| KerendiaFinerenone | 179 | $129,309 |
| Repatha SureclickEvolocumab | 182 | $104,937 |
| Taltz AutoinjectorIxekizumab | 12 | $79,068 |
| VascepaIcosapent Ethyl | 165 | $56,544 |
| Icosapent Ethyl | 283 | $51,595 |
| Praluent PenAlirocumab | 70 | $35,741 |
| XareltoRivaroxaban | 35 | $31,619 |
| ProliaDenosumab | 19 | $29,588 |
| UbrelvyUbrogepant | 24 | $27,484 |
| Evenity (2 Syringes)Romosozumab-Aqqg | 12 | $27,466 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Corcept TherapeuticsKorlym | $63,437 | $2,036,24678 claims |
| Novo NordiskOzempic, Rybelsus | $1,720 | $781,994798 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $451 | $324,191506 claims |
| BayerKerendia | $286 | $129,309179 claims |
| AmgenProlia, Evenity (2 Syringes) | $932 | $57,05431 claims |
| AbbVieUbrelvy, Linzess | $488 | $40,23639 claims |
| Johnson & JohnsonXarelto | $143 | $31,61935 claims |
| Boehringer IngelheimJardiance | $75 | $27,33633 claims |
| Esperion Therapeutics, Inc.Nexletol, Nexlizet | $121 | $24,77460 claims |
| PfizerEliquis | $20 | $16,38017 claims |
| NovartisEntresto | $61 | $9,28815 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,634 family providers in California.
Other family in Escondido
- Lori RobertsonChino Hills$475K
- Annette ShonLos Angeles$406K
- Lisa HigginsHanford$311K
- Jennifer TougasBakersfield$302K
- Kim SchaferSacramento$288K
- Dawn MeyerSan Diego$270K
- Jennifer KangCerritos$255K
- Erin DwyerSan Diego$189K
- Phyllis CasonLos Angeles$187K
- Gabriel SchwartzSan Francisco$166K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.